Eclipse Bioinnovations

About Eclipse Bioinnovations

Eclipse Bioinnovations, Inc. operates as a specialized genomics technology company, providing products and services to biopharma and academic clients. Founded in 2017 by Peter Chu, Alexander Shishkin, Eric Van Nostrand, and Gene Yeo, the company originated from technology developed in Professor Yeo's laboratory at the University of California San Diego. The company's inception was driven by the high demand from other scientists for the eCLIP analysis technology developed in Yeo's lab, which the lab couldn't handle on its own. Chu, the CEO, is a scientist-turned-entrepreneur with 20 years of experience in biotech, while Shishkin has a background in molecular biology at institutions like the Broad Institute and Illumina. The company's initial research was supported by $4.5 million in grants, and it has since raised a total of $14 million over four funding rounds, including a Series A round in March 2022.

The company's business model is centered on offering its end-to-end RNA genomics solutions as both services and kits. It serves academic institutions like Harvard and Stanford, as well as pharmaceutical giants such as Alnylam Pharmaceuticals and Genentech. Clients typically send cell samples, and Eclipsebio performs the processing, sequencing, and data analysis, delivering a comprehensive data package. This enables researchers to understand RNA interactions, modifications, structure, and translation. The company offers its solutions as end-to-end partnerships, including custom assay development for biopharma companies, and as a la carte services for academic researchers.

Eclipsebio's core technology platform, eCLIP-seq, identifies RNA binding protein gene partners and maps. The company has developed a portfolio of products and services around this, including RBP-eCLIP for mapping protein-RNA interactions and m6A-eCLIP for profiling RNA modifications. A key offering is the eSHAPE product family, launched in February 2023, which measures RNA secondary structure, a critical factor in the development of RNA therapeutics and small molecule drugs. The eRibo platform provides methods to profile protein translation, offering insights beyond traditional analysis. In 2024, Eclipsebio launched the eMERGE platform, an end-to-end solution for characterizing and optimizing RNA-based therapeutics, and eSENSE dsRNA for quantifying contaminants in RNA vaccines and therapies. The company also offers eVERSE, a portfolio of reproducible, large-scale datasets specifically designed for training AI models in drug discovery.